Alaunos Therapeutics (TCRT) Prices Public Offering of Common Stock for Gross Proceeds of Approximately $15.7 Million
- Wall Street closes green as GDP data eases recession worries
- Intel sinks after forecasting weaker than expected start to 2023
- Hasbro cuts 15% of workforce, warns for Q4 on weak consumer business
- Visa reports better than expected Q1 results
- Bulls win Tesla 'Super Bowl' on demand as bears focus on plunging gross margins
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced the pricing of its underwritten public offering of approximately 24,228,719 shares of its common stock for gross proceeds of approximately $15.7 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Alaunos. All of the shares of common stock are being offered by Alaunos. The offering is expected to close on or about December 1, 2022, subject to customary closing conditions. In addition, Alaunos has granted to the underwriter a 30-day option to purchase up to 3,634,307 additional shares of its common stock.
Alaunos intends to use the net proceeds from the offering to fund the continued development of the product candidates in its pipeline, and for working capital, capital expenditures and general corporate purposes.
Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.
The underwriter may offer the shares from time to time for sale in one or more transactions on the Nasdaq Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices.
A registration statement on Form S-3 (No. 333-266841) relating to these securities has been filed with the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective on September 7, 2022. The offering is being made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available free of charge by visiting EDGAR on the SEC’s website at www.sec.gov.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Village Farms (VFF) Prices 18.35M Share Offering at $1.35/sh
- Dare Bioscience (DARE) Announces Publication of Data from Phase 1 Trial of DARE-HRT1
- Soleno Therapeutics (SLNO) Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Related EntitiesCantor Fitzgerald, S3, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!